#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypoxic-ischaemic encephalopathy Herpes simplex Chronic kidney disease Ovarian epithelial cancer B precursor type acute leukaemia Leukocyte adhesion deficiency type I Autologous haematopoietic stem cell transplant Myelofibrosis Muscular dystrophy Stevens-Johnson syndrome Basal cell naevus syndrome Primary biliary cholangitis Monogenic diabetes Autoimmune disorder Spinal cord injury cervical More trials…

    Learn about Rare Diseases

    Alternating hemiplegia of childhood – Trials in Disease Immunodeficiency congenital – Treatment Hypereosinophilic syndrome – Trials in Disease Chronic granulomatous disease – Basic Information Wiskott-Aldrich syndrome – Trials in Disease Mantle cell lymphoma – Basic Information Turner’s syndrome – Trials in Disease Lymphatic malformation Undifferentiated sarcoma – Basic Information Pelizaeus-Merzbacher disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dostarlimab Isotretinoin Ranitidine Acou085 Bms-986288 Aspergillus Fumigatus Bidridistrogene Xeboparvovec Enomimeran Tezepelumab Mk-1200 Alirocumab Vx-670 Terbinafine NVG-2089 Pegipanermin Itolizumab Montelukast Sodium Altizide Ethambutol Hydrochloride Amy109 More therapies…

    Learn about Your Condition

    Alcohol abuse Anaplastic thyroid cancer Injection site pain Hernia repair Pancreatitis chronic Follicular lymphoma stage III Medulloblastoma Arterial tortuosity syndrome Hidradenitis Basal cell naevus syndrome Thymoma malignant Renal cancer recurrent Proteinuria Hypopituitarism Follicular lymphoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Tucatinib
    • Eribulin Mesylate
    Spain

  • A study to evaluate the safety of OMN6 in patients with pneumonia caused by Acinetobacter baumannii bacteria.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pneumonia bacterial
    Investigated Drugs:
    • Saline
    Greece Hungary Italy

  • A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Rilvegostomig
    • Ramucirumab
    • Infliximab
    France Italy Spain

  • Modafinil for Severe Fatigue in Patients with Quiescent Inflammatory Bowel Disease

    Recruiting

    4 1 1
    Investigated Diseases:
    • Chronic fatigue syndrome
    Investigated Drugs:
    • Modafinil
    • Placebo
    The Netherlands

  • Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

    Recruiting

    3 1 1
    Investigated Drugs:
    • Cenegermin
    • Oxybuprocaine Hydrochloride
    • Tetracaine Hydrochloride
    Czechia France Germany Hungary Italy The Netherlands +2

  • Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    • Obesity
    Investigated Drugs:
    • HRS 9531
    Bulgaria Czechia Germany Hungary Poland Spain
Previous Page
1 … 18 19 20 21 22 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!